ArticleBlood cancer journal2026

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Doris K Hansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.